FTO in Lung Cancer: Its Progression and Therapeutic Potential


Citar

Texto integral

Resumo

One of the most fatal and frequent malignancies on the planet is lung cancer. Its occurrence and development are the results of multifactorial and multigenic interactions. In recent years, RNA N6-methyladenosine transferase (FTO) has gained significant attention in the field of oncology. FTO is the first RNA demethylase to be found to control target mRNA demethylation. The growth, proliferation, and metastasis of tumor cells are greatly influenced by FTO. Recent studies have found that imbalanced m6A methylation regulatory proteins can induce disruption of downstream RNA metabolism, strongly affecting tumor development. This paper provides an overview of the relationship between FTO and lung cancer, discussing the mechanisms by which FTO is involved in lung cancer and its potential clinical applications.

Sobre autores

Xue-Fen Chen

Geriatrics Respiratory Medicine Department, First Affiliated Hospital of GuangXi Medical University

Email: info@benthamscience.net

Chen Gong

Geriatrics Respiratory Medicine Department, First Affiliated Hospital of GuangXi Medical University

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Frayling, T.M.; Timpson, N.J.; Weedon, M.N.; Zeggini, E.; Freathy, R.M.; Lindgren, C.M.; Perry, J.R.B.; Elliott, K.S.; Lango, H.; Rayner, N.W.; Shields, B.; Harries, L.W.; Barrett, J.C.; Ellard, S.; Groves, C.J.; Knight, B.; Patch, A.M.; Ness, A.R.; Ebrahim, S.; Lawlor, D.A.; Ring, S.M.; Ben-Shlomo, Y.; Jarvelin, M.R.; Sovio, U.; Bennett, A.J.; Melzer, D.; Ferrucci, L.; Loos, R.J.F.; Barroso, I.; Wareham, N.J.; Karpe, F.; Owen, K.R.; Cardon, L.R.; Walker, M.; Hitman, G.A.; Palmer, C.N.A.; Doney, A.S.F.; Morris, A.D.; Smith, G.D.; Hattersley, A.T.; McCarthy, M.I. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science, 2007, 316(5826), 889-894. doi: 10.1126/science.1141634 PMID: 17434869
  2. Chen, J.; Du, B. Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression. J. Cancer Res. Clin. Oncol., 2019, 145(1), 19-29. doi: 10.1007/s00432-018-2796-0 PMID: 30465076
  3. Kang, Y.; Liu, F.; Liu, Y. Is FTO gene variant related to cancer risk independently of adiposity? An updated meta-analysis of 129,467 cases and 290,633 controls. Oncotarget, 2017, 8(31), 50987-50996. doi: 10.18632/oncotarget.16446 PMID: 28881622
  4. Zhang, G.; Karns, R.; Narancic, N.S.; Sun, G.; Cheng, H.; Missoni, S.; Durakovic, Z.; Rudan, P.; Chakraborty, R.; Deka, R. Common SNPs in FTO gene are associated with obesity related anthropometric traits in an island population from the eastern Adriatic coast of Croatia. PLoS One, 2010, 5(4), e10375. doi: 10.1371/journal.pone.0010375 PMID: 20442772
  5. Jia, G.; Fu, Y.; Zhao, X.; Dai, Q.; Zheng, G.; Yang, Y.; Yi, C.; Lindahl, T.; Pan, T.; Yang, Y.G.; He, C. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol., 2011, 7(12), 885-887. doi: 10.1038/nchembio.687 PMID: 22002720
  6. Hess, M.E.; Hess, S.; Meyer, K.D.; Verhagen, L.A.W.; Koch, L.; Brönneke, H.S.; Dietrich, M.O.; Jordan, S.D.; Saletore, Y.; Elemento, O.; Belgardt, B.F.; Franz, T.; Horvath, T.L.; Rüther, U.; Jaffrey, S.R.; Kloppenburg, P.; Brüning, J.C. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat. Neurosci., 2013, 16(8), 1042-1048. doi: 10.1038/nn.3449 PMID: 23817550
  7. Ben-Haim, M.S.; Moshitch-Moshkovitz, S.; Rechavi, G. FTO: linking m6A demethylation to adipogenesis. Cell Res., 2015, 25(1), 3-4. doi: 10.1038/cr.2014.162 PMID: 25475057
  8. Zheng, G.; Dahl, J.A.; Niu, Y.; Fedorcsak, P.; Huang, C.M.; Li, C.J.; Vågbø, C.B.; Shi, Y.; Wang, W.L.; Song, S.H.; Lu, Z.; Bosmans, R.P.G.; Dai, Q.; Hao, Y.J.; Yang, X.; Zhao, W.M.; Tong, W.M.; Wang, X.J.; Bogdan, F.; Furu, K.; Fu, Y.; Jia, G.; Zhao, X.; Liu, J.; Krokan, H.E.; Klungland, A.; Yang, Y.G.; He, C. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell, 2013, 49(1), 18-29. doi: 10.1016/j.molcel.2012.10.015 PMID: 23177736
  9. Zhao, B.S.; Roundtree, I.A.; He, C. Post-transcriptional gene regulation by mRNA modifications. Nat. Rev. Mol. Cell Biol., 2017, 18(1), 31-42. doi: 10.1038/nrm.2016.132 PMID: 27808276
  10. Wang, T.; Kong, S.; Tao, M.; Ju, S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol. Cancer, 2020, 19(1), 88. doi: 10.1186/s12943-020-01204-7 PMID: 32398132
  11. Gao, R.; Ye, M.; Liu, B.; Wei, M.; Ma, D.; Dong, K. m6A modification: A double-edged sword in tumor development. Front. Oncol., 2021, 11, 679367. doi: 10.3389/fonc.2021.679367 PMID: 34381710
  12. Rajan, K.S.; Ramasamy, S.; Garikipati, V.N.S.; Suvekbala, V. The cardiac methylome: A hidden layer of RNA modifications to regulate gene expression. J. Mol. Cell. Cardiol., 2021, 152, 40-51. doi: 10.1016/j.yjmcc.2020.11.011 PMID: 33279505
  13. Zaccara, S.; Ries, R.J.; Jaffrey, S.R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol., 2019, 20(10), 608-624. doi: 10.1038/s41580-019-0168-5 PMID: 31520073
  14. Wei, W.; Ji, X.; Guo, X.; Ji, S. Regulatory role of N6-methyladenosine (m6A) methylation in RNA processing and human diseases. J. Cell. Biochem., 2017, 118(9), 2534-2543. doi: 10.1002/jcb.25967 PMID: 28256005
  15. Zheng, Q.K.; Ma, C.; Ullah, I., Jnr; Hu, K.; Ma, R.J.; Zhang, N.; Sun, Z.G. Roles of N6‐methyladenosine demethylase FTO in malignant tumors progression. OncoTargets Ther., 2021, 14, 4837-4846. doi: 10.2147/OTT.S329232 PMID: 34556998
  16. Natalia, P.; Stephanie, S.; Justin, J-L.W. Aberrant expression of enzymes regulating m6A mRNA methylation: Implication in cancer. Cancer Biol. Med., 2018, 15(4), 323-334. doi: 10.20892/j.issn.2095-3941.2018.0365 PMID: 30766746
  17. Wei, H.; Li, Z.; Liu, F.; Wang, Y.; Ding, S.; Chen, Y.; Liu, J. The role of FTO in tumors and its research progress. Curr. Med. Chem., 2022, 29(5), 924-933. doi: 10.2174/0929867328666210714153046 PMID: 34269659
  18. Shen, F.; Huang, W.; Huang, J.T.; Xiong, J.; Yang, Y.; Wu, K.; Jia, G.F.; Chen, J.; Feng, Y.Q.; Yuan, B.F.; Liu, S.M. Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5. J. Clin. Endocrinol. Metab., 2015, 100(1), E148-E154. doi: 10.1210/jc.2014-1893 PMID: 25303482
  19. Elkashef, S.M.; Lin, A.P.; Myers, J.; Sill, H.; Jiang, D.; Dahia, P.L.M.; Aguiar, R.C.T. IDH mutation, competitive inhibition of FTO, and RNA methylation. Cancer Cell, 2017, 31(5), 619-620. doi: 10.1016/j.ccell.2017.04.001 PMID: 28486104
  20. Li, Z.; Weng, H.; Su, R.; Weng, X.; Zuo, Z.; Li, C.; Huang, H.; Nachtergaele, S.; Dong, L.; Hu, C.; Qin, X.; Tang, L.; Wang, Y.; Hong, G.M.; Huang, H.; Wang, X.; Chen, P.; Gurbuxani, S.; Arnovitz, S.; Li, Y.; Li, S.; Strong, J.; Neilly, M.B.; Larson, R.A.; Jiang, X.; Zhang, P.; Jin, J.; He, C.; Chen, J. FTO plays an oncogenic role in acute myeloid leukemia as a N 6 -methyladenosine RNA demethylase. Cancer Cell, 2017, 31(1), 127-141. doi: 10.1016/j.ccell.2016.11.017 PMID: 28017614
  21. Tian, R.; Zhang, S.; Sun, D.; Bei, C.; Li, D.; Zheng, C.; Song, X.; Chen, M.; Tan, S.; Zhu, X.; Zhang, H. M6A demethylase FTO plays a tumor suppressor role in thyroid cancer. DNA Cell Biol., 2020, 39(12), 2184-2193. doi: 10.1089/dna.2020.5956 PMID: 33054406
  22. Cui, Q.; Shi, H.; Ye, P.; Li, L.; Qu, Q.; Sun, G.; Sun, G.; Lu, Z.; Huang, Y.; Yang, C.G.; Riggs, A.D.; He, C.; Shi, Y. m 6 A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep., 2017, 18(11), 2622-2634. doi: 10.1016/j.celrep.2017.02.059 PMID: 28297667
  23. Chen, M.; Wei, L.; Law, C.T.; Tsang, F.H.C.; Shen, J.; Cheng, C.L.H.; Tsang, L.H.; Ho, D.W.H.; Chiu, D.K.C.; Lee, J.M.F.; Wong, C.C.L.; Ng, I.O.L.; Wong, C.M. RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2. Hepatology, 2018, 67(6), 2254-2270. doi: 10.1002/hep.29683 PMID: 29171881
  24. Ma, J.; Yang, F.; Zhou, C.; Liu, F.; Yuan, J.; Wang, F.; Wang, T.; Xu, Q.; Zhou, W.; Sun, S. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6‐methyladenosine‐dependent primary MicroRNA processing. Hepatology, 2017, 65(2), 529-543. doi: 10.1002/hep.28885 PMID: 27774652
  25. Zou, D.; Dong, L.; Li, C.; Yin, Z.; Rao, S.; Zhou, Q. The m6A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int., 2019, 19(1), 321. doi: 10.1186/s12935-019-1045-1 PMID: 31827395
  26. Tang, H.; Dong, X.; Hassan, M.; Abbruzzese, J.L.; Li, D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol. Biomarkers Prev., 2011, 20(5), 779-792. doi: 10.1158/1055-9965.EPI-10-0845 PMID: 21357378
  27. Herquelot, E.; Bodin, J.; Petit, A.; Ha, C.; Leclerc, A.; Goldberg, M.; Zins, M.; Roquelaure, Y.; Descatha, A. Long-term persistence of knee pain and occupational exposure in two large prospective cohorts of workers. BMC Musculoskelet. Disord., 2014, 15(1), 411. doi: 10.1186/1471-2474-15-411 PMID: 25475051
  28. Niu, Y.; Lin, Z.; Wan, A.; Chen, H.; Liang, H.; Sun, L.; Wang, Y.; Li, X.; Xiong, X.; Wei, B.; Wu, X.; Wan, G. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol. Cancer, 2019, 18(1), 46. doi: 10.1186/s12943-019-1004-4 PMID: 30922314
  29. Zhang, Z.; Zhou, D.; Lai, Y.; Liu, Y.; Tao, X.; Wang, Q.; Zhao, G.; Gu, H.; Liao, H.; Zhu, Y.; Xi, X.; Feng, Y. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett., 2012, 319(1), 89-97. doi: 10.1016/j.canlet.2011.12.033 PMID: 22222214
  30. Chong, W.; Shang, L.; Liu, J.; Fang, Z.; Du, F.; Wu, H.; Liu, Y.; Wang, Z.; Chen, Y.; Jia, S.; Chen, L.; Li, L.; Chen, H. m 6 A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. Theranostics, 2021, 11(5), 2201-2217. doi: 10.7150/thno.52717 PMID: 33500720
  31. Li, J.; Zhu, L.; Shi, Y.; Liu, J.; Lin, L.; Chen, X. m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am. J. Transl. Res., 2019, 11(9), 6084-6092. PMID: 31632576
  32. Zhuang, C.; Zhuang, C.; Luo, X.; Huang, X.; Yao, L.; Li, J.; Li, Y.; Xiong, T.; Ye, J.; Zhang, F.; Gui, Y. N6‐methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO ‐ PGC ‐1α signalling axis. J. Cell. Mol. Med., 2019, 23(3), 2163-2173. doi: 10.1111/jcmm.14128 PMID: 30648791
  33. Huang, Y.; Su, R.; Sheng, Y.; Dong, L.; Dong, Z.; Xu, H.; Ni, T.; Zhang, Z.S.; Zhang, T.; Li, C.; Han, L.; Zhu, Z.; Lian, F.; Wei, J.; Deng, Q.; Wang, Y.; Wunderlich, M.; Gao, Z.; Pan, G.; Zhong, D.; Zhou, H.; Zhang, N.; Gan, J.; Jiang, H.; Mulloy, J.C.; Qian, Z.; Chen, J.; Yang, C.G. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell, 2019, 35(4), 677-691.e10. doi: 10.1016/j.ccell.2019.03.006 PMID: 30991027
  34. Malapelle, U.; Morra, F.; Ilardi, G.; Visconti, R.; Merolla, F.; Cerrato, A.; Napolitano, V.; Monaco, R.; Guggino, G.; Monaco, G.; Staibano, S.; Troncone, G.; Celetti, A. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. Lung Cancer, 2017, 107, 41-49. doi: 10.1016/j.lungcan.2016.06.015 PMID: 27372520
  35. Li, J.; Han, Y.; Zhang, H.; Qian, Z.; Jia, W.; Gao, Y.; Zheng, H.; Li, B. The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem. Biophys. Res. Commun., 2019, 512(3), 479-485. doi: 10.1016/j.bbrc.2019.03.093 PMID: 30905413
  36. Ding, Y.; Qi, N.; Wang, K.; Huang, Y.; Liao, J.; Wang, H.; Tan, A.; Liu, L.; Zhang, Z.; Li, J.; Kong, J.; Qin, S.; Jiang, Y. FTO facilitates lung adenocarcinoma cell progression by activating cell migration through mRNA demethylation. OncoTargets Ther., 2020, 13, 1461-1470. doi: 10.2147/OTT.S231914 PMID: 32110044
  37. Shi, H.; Zhao, J.; Han, L.; Xu, M.; Wang, K.; Shi, J.; Dong, Z. Retrospective study of gene signatures and prognostic value of m6A regulatory factor in non-small cell lung cancer using TCGA database and the verification of FTO. Aging, 2020, 12(17), 17022-17037. doi: 10.18632/aging.103622 PMID: 32903217
  38. Pei, Y.; Lou, X.; Li, K.; Xu, X.; Guo, Y.; Xu, D.; Yang, Z.; Xu, D.; Cui, W.; Zhang, D. Peripheral blood leukocyte n6-methyladenosine is a noninvasive biomarker for non-small-cell lung carcinoma. OncoTargets Ther., 2020, 13, 11913-11921. doi: 10.2147/OTT.S267344 PMID: 33239892
  39. Gao, M.; Qi, Z.; Feng, W.; Huang, H.; Xu, Z.; Dong, Z.; Xu, M.; Han, J.; Kloeber, J.A.; Huang, J.; Lou, Z.; Liu, S. m6A demethylation of cytidine deaminase APOBEC3B mRNA orchestrates arsenic-induced mutagenesis. J. Biol. Chem., 2022, 298(2), 101563. doi: 10.1016/j.jbc.2022.101563 PMID: 34998823
  40. Wang, Y.; Li, M.; Zhang, L.; Chen, Y.; Zhang, S. m6A demethylase FTO induces NELL2 expression by inhibiting E2F1 m6A modification leading to metastasis of non-small cell lung cancer. Mol. Ther. Oncolytics, 2021, 21, 367-376. doi: 10.1016/j.omto.2021.04.011 PMID: 34169146
  41. Liu, J.; Ren, D.; Du, Z.; Wang, H.; Zhang, H.; Jin, Y. m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem. Biophys. Res. Commun., 2018, 502(4), 456-464. doi: 10.1016/j.bbrc.2018.05.175 PMID: 29842885
  42. Fu, Y.; Liu, L.; Wu, H.; Zheng, Y.; Zhan, H.; Li, L. LncRNA GAS5 regulated by FTO-mediated m6A demethylation promotes autophagic cell death in NSCLC by targeting UPF1/BRD4 axis. Mol. Cell. Biochem., 2023. doi: 10.1007/s11010-023-04748-6 PMID: 37120495
  43. Lin, S.; Choe, J.; Du, P.; Triboulet, R.; Gregory, R.I. The m 6 A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell, 2016, 62(3), 335-345. doi: 10.1016/j.molcel.2016.03.021 PMID: 27117702
  44. Qiu, F.S.; He, J.Q.; Zhong, Y.S.; Guo, M.Y.; Yu, C.H. Implications of m6A methylation and microbiota interaction in non-small cell lung cancer: From basics to therapeutics. Front. Cell. Infect. Microbiol., 2022, 12, 972655. doi: 10.3389/fcimb.2022.972655 PMID: 36118041
  45. Yin, H.; Zhang, X.; Yang, P.; Zhang, X.; Peng, Y.; Li, D.; Yu, Y.; Wu, Y.; Wang, Y.; Zhang, J.; Ding, X.; Wang, X.; Yang, A.; Zhang, R. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat. Commun., 2021, 12(1), 1394. doi: 10.1038/s41467-021-21514-8 PMID: 33654093
  46. Liu, Z.; Wang, T.; She, Y.; Wu, K.; Gu, S.; Li, L.; Dong, C.; Chen, C.; Zhou, Y. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol. Cancer, 2021, 20(1), 105. doi: 10.1186/s12943-021-01398-4 PMID: 34416901
  47. Zhao, Y.; You, S.; Yu, Y.Q.; Zhang, S.; Li, P.T.; Ye, Y.H.; Zhao, W.X.; Li, J.; Li, Q.; Jiao, H.; Chi, X.Q.; Wang, X.M. Decreased nuclear expression of FTO in human primary hepatocellular carcinoma is associated with poor prognosis. Int. J. Clin. Exp. Pathol., 2019, 12(9), 3376-3383. PMID: 31934180
  48. Yin, H.; Hong, H.; Yin, P.; Lu, W.; Niu, S.; Chen, X.; Xia, Y.; Jiang, P.; Huang, Z. Increased levels of N6-methyladenosine in peripheral blood RNA: a perspective diagnostic biomarker and therapeutic target for non-small cell lung cancer. Clin. Chem. Lab. Med., 2023, 61(3), 473-484. doi: 10.1515/cclm-2022-1033 PMID: 36542027
  49. Jin, L.; Chen, C.; Yao, J.; Yu, Z.; Bu, L. The RNA N 6 ‐methyladenosine modulator HNRNPA2B1 is involved in the development of non‐small cell lung cancer. Clin. Exp. Pharmacol. Physiol., 2022, 49(3), 329-340. doi: 10.1111/1440-1681.13608 PMID: 34717005
  50. Wang, L.; Feng, X.; Jiao, Z.; Gan, J.; Meng, Q. Characterization of the prognostic and diagnostic values of ALKBH family members in non-small cell lung cancer. Pathol. Res. Pract., 2022, 231, 153809. doi: 10.1016/j.prp.2022.153809 PMID: 35180653
  51. And Alternative Medicine. E.C. Retracted: Diagnostic value of fto combined with cea or cyfra21-1 in nonsmall cell lung cancer. Evid. Based Complement. Alternat. Med., 2023, 2023, 9843134. PMID: 37387935
  52. Chen, B.; Ye, F.; Yu, L.; Jia, G.; Huang, X.; Zhang, X.; Peng, S.; Chen, K.; Wang, M.; Gong, S.; Zhang, R.; Yin, J.; Li, H.; Yang, Y.; Liu, H.; Zhang, J.; Zhang, H.; Zhang, A.; Jiang, H.; Luo, C.; Yang, C.G. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J. Am. Chem. Soc., 2012, 134(43), 17963-17971. doi: 10.1021/ja3064149 PMID: 23045983
  53. Mu, X.; Zhao, Q.; Chen, W.; Zhao, Y.; Yan, Q.; Peng, R.; Zhu, J.; Yang, C.; Lan, K.; Gu, X.; Wang, Y. IL-37 confers anti-tumor activity by regulation of m6A methylation. Front. Oncol., 2021, 10, 526866. doi: 10.3389/fonc.2020.526866 PMID: 33489865
  54. Li, N.; Chen, X.; Liu, Y.; Zhou, T.; Li, W. Gene characteristics and prognostic values of m6A RNA methylation regulators in nonsmall cell lung cancer. J. Healthc. Eng., 2021, 2021, 1-12. doi: 10.1155/2021/2257066 PMID: 34367534
  55. Zhang, D.; Zhang, D.; Wang, C.; Yang, X.; Zhang, R.; Li, Q.; Xiong, Y. Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma. Eur. J. Cancer Prev., 2022, 31(4), 354-362. doi: 10.1097/CEJ.0000000000000717 PMID: 34519693
  56. Meng, Q.; Wang, S.; Zhou, S.; Liu, H.; Ma, X.; Zhou, X.; Liu, H.; Xu, C.; Jiang, W. Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancer. Pharmacogenomics J., 2020, 20(2), 227-234. doi: 10.1038/s41397-019-0110-4 PMID: 31624334
  57. Nagano, T.; Tachihara, M.; Nishimura, Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells, 2018, 7(11), 212. doi: 10.3390/cells7110212 PMID: 30445769
  58. Xiao, P.; Liu, Y.; Han, W.; Hu, Y.; Zhang, B.; Liu, W. Exosomal delivery of FTO confers gefitinib resistance to recipient cells through ABCC10 regulation in an m6A-dependent manner. Mol. Cancer Res., 2021, 19(4), 726-738. doi: 10.1158/1541-7786.MCR-20-0541 PMID: 33563765
  59. Wang, Q.; Zhang, L.; Su, Z.; Li, W.; Jia, Y.; Zhang, J. Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression. Pulm. Pharmacol. Ther., 2023, 82, 102227. doi: 10.1016/j.pupt.2023.102227 PMID: 37330168
  60. Huang, Y.; Yan, J.; Li, Q.; Li, J.; Gong, S.; Zhou, H.; Gan, J.; Jiang, H.; Jia, G.F.; Luo, C.; Yang, C.G. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res., 2015, 43(1), 373-384. doi: 10.1093/nar/gku1276 PMID: 25452335
  61. Chen, H.; Jia, B.; Zhang, Q.; Zhang, Y. Meclofenamic acid restores gefinitib sensitivity by downregulating breast cancer resistance protein and multidrug resistance protein 7 via FTO/m6A-Demethylation/c-Myc in non-small cell lung cancer. Front. Oncol., 2022, 12, 870636. doi: 10.3389/fonc.2022.870636 PMID: 35530301

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024